260). This antibody has been widely used in experimental studies to demonstrate HH dependency in tumour models, but it has not advanced to clinical settings. Recently, a novel neutralising antibody acting on SHH and IHH with low picomolar affinity has been reported (Ref. 261). Moreover, two small molecules have been described; robotnikinin binds to and inhibits SHH protein (Ref. 262), whereas RU-SKI, an inhibitor of HH acyltransferase, hampers SHH palmitoylation and blocks HH signalling (Ref. 263). Here, SHH is linked to neoplasm.